Apimeds Pharmaceuticals US, Inc. logo

Apimeds Pharmaceuticals US, Inc.(APUS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.23
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for APUS

11/13/2026: APUS (1-star) is currently NOT-A-BUY. Pass it for now.

Apimeds Pharmaceuticals US, Inc. is a micro-cap clinical-stage biopharmaceutical company developing non-opioid pain therapies alongside digital asset treasury operations. The company's main clinical asset is Apitox, a purified bee venom treatment aimed at knee osteoarthritis. While its non-opioid pipeline offers a differentiated therapeutic approach and secondary digital asset exposure provides diversification, the company remains pre-revenue with ongoing net losses and high share volatility. Key risks include heavy reliance on clinical trial success, regulatory hurdles, and substantial dilution exposure. The stock suits speculative or momentum-oriented investors willing to accept high volatility, requiring close monitoring of clinical milestones and funding updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitLack of commercial revenues and early clinical stage limit traditional growth visibility.
Momentum investorStrong fit while signal remains positiveMicro-cap status and low float can trigger sharp price movements on news catalysts.
Value investorWeak fitOngoing net losses and absence of earnings make traditional value metrics inapplicable.
Dividend investorWeak fitThe company pays no dividends and retains all capital for research.
Low-risk investorWeak fitHigh share volatility and clinical trial uncertainties present significant capital loss risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap clinical-stage shares experience extreme intraday and historical price swings.
Valuation riskHighValuations are driven by speculative clinical milestones rather than fundamental earnings.
Competition risk (large pharma pain management)HighWell-capitalized pharmaceutical competitors dominate the therapeutic landscape.
Business qualityMediumThe company remains pre-revenue with unproven commercial scalability.
Dividend incomeLow / noneNo dividend distributions are made to investors.
Execution riskHighClinical trial success and regulatory approvals are required to validate the business model.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.37M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 3.6M shares
Beta -
52 Weeks Range 1.51 - 40.31
Updated Date 11/15/2026
52 Weeks Range 1.51 - 40.31
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -36.03

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -36.93%
Avg. Invested days 9
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
APUS receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
APUS has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-331.7%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
APUS's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
APUS's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-331.7%, negative) and free-cash-flow growth (-1124.6%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 4.6% and approximately 135.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 58.84% supports management-shareholder alignment.

Unit Economics (Per $1K Revenue)

★★★★★
APUS generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
APUS has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Biopharmaceutical ResearchFuture commercialization and licensing of Apitox for osteoarthritis and inflammatory indications.Currently pre-revenue; future income depends entirely on drug approvals and sales.
Digital Asset SolutionsBlockchain-backed institutional infrastructure and crypto-asset treasury management services.Provides secondary exposure to digital asset markets through corporate treasury activities.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 17.66M
Price to Sales(TTM) -
Enterprise Value 17.66M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 1.51M
Shares Floating 2.05M
Shares Outstanding 1.51M
Shares Floating 2.05M
Percent Insiders 58.84
Percent Institutions 4.57

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.